Literature DB >> 7629870

Effect of human T-lymphotropic virus type I infection on non-Hodgkin's lymphoma incidence.

F R Cleghorn1, A Manns, R Falk, P Hartge, B Hanchard, N Jack, E Williams, E Jaffe, F White, C Bartholomew.   

Abstract

BACKGROUND: We previously reported from a case-control analysis that T-cell non-Hodgkin's lymphoma (NHL) was strongly associated with human T-lymphotropic virus type I (HTLV-I) infection in Jamaica and Trinidad and that the relative risk for HTLV-I infection was very high in younger patients.
PURPOSE: The objective of this study was to estimate the age-specific incidence rates of NHL among HTLV-I-infected and HTLV-I-uninfected adults in Jamaica and Trinidad.
METHODS: Population rates of HTLV-I infection were calculated from available census reports and serosurvey data. Incidence rates for NHL were calculated from all incident cases in Jamaica during 1984-1987 (n = 135) and from all incident cases in Trinidad during 1986-1990 (n = 117). Using biopsy material, we determined whether the immunophenotype of the tumor cells was T cell, B cell, or other. NHL incidence rates were computed according to HTLV-I status, age, sex, and tumor phenotype for each country separately and for both countries combined by weighting to the relative population size of each country.
RESULTS: The age-standardized NHL incidence rate (mean +/- SE) in Jamaica was 1.9 +/- 0.2 per 100,000 person-years (PY). In Trinidad, the rate was 2.9 +/- 0.4 per 100,000 PY. Overall, the incidence of NHL increased with age and was higher in males than in females. In the HTLV-I-infected population, the incidence of NHL was inversely related to age, and age-specific rates were higher in males than in females. The NHL incidence in those estimated to have acquired HTLV-I infection in childhood, however, showed no sex difference, and one in 1300 such carriers (95% confidence interval: one in 1100 to one in 1600) per annum were estimated to be at such risk. For T-cell NHL, as proxy for adult T-cell lymphoma/leukemia, incidence was highest in those patients infected with HTLV-I early in life (perinatally or via breast milk), with high, sustained risk from early adulthood in both sexes.
CONCLUSIONS: While overall NHL incidence rates reveal that HTLV-I endemicity does not impose an exaggerated lymphoma burden on these populations, the risk for lymphoma among carriers who acquire infection early in life is dramatic and is consistent with the hypothesis that virus exposure early in life is most important for lymphoma-genesis. IMPLICATIONS: Studies of HTLV-I carriers known to be infected in childhood may provide insight into markers intermediate in the lympho-magnetic process. Strategies to disrupt early-life transmission of HTLV-I, notably mother-infant transmission, may be critical in reducing the burden of lymphoreticular disease in these populations.

Entities:  

Mesh:

Year:  1995        PMID: 7629870     DOI: 10.1093/jnci/87.13.1009

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  14 in total

Review 1.  HTLV-1 infections.

Authors:  C R Bangham
Journal:  J Clin Pathol       Date:  2000-08       Impact factor: 3.411

Review 2.  Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation.

Authors:  Michael D Lairmore; Lee Silverman; Lee Ratner
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

3.  Screening of promising chemotherapeutic candidates against human adult T-cell leukemia/lymphoma from plants: active principles from Physalis pruinosa and structure-activity relationships with withanolides.

Authors:  Daisuke Nakano; Kenji Ishitsuka; Takahiro Hatsuse; Ryota Tsuchihashi; Masafumi Okawa; Hikaru Okabe; Kazuo Tamura; Junei Kinjo
Journal:  J Nat Med       Date:  2011-05-14       Impact factor: 2.343

Review 4.  Advances in interleukin 2 receptor targeted treatment.

Authors:  J C Morris; T A Waldmann
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

5.  Clinical manifestations in individuals with recent diagnosis of HTLV type I infection.

Authors:  Shelene K W Poetker; Aurelia F Porto; Silvana P Giozza; Andre L Muniz; Marina F Caskey; Edgar M Carvalho; Marshall J Glesby
Journal:  J Clin Virol       Date:  2011-03-08       Impact factor: 3.168

Review 6.  Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma.

Authors:  A J Swerdlow
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

Review 7.  Complicated and fatal Strongyloides infection in Canadians: risk factors, diagnosis and management.

Authors:  Sue Lim; Kevin Katz; Sigmund Krajden; Milan Fuksa; Jay S Keystone; Kevin C Kain
Journal:  CMAJ       Date:  2004-08-31       Impact factor: 8.262

8.  Hospital admissions for human T-cell lymphotropic virus type-1 (HTLV-1) associated diseases in Dominica.

Authors:  O Adedayo; G Grell; P Bellot
Journal:  Postgrad Med J       Date:  2003-06       Impact factor: 2.401

Review 9.  CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas.

Authors:  Alexandra S Onea; Ali R Jazirehi
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

Review 10.  Epidemiology and Etiology of Leukemia and Lymphoma.

Authors:  Jordan A Baeker Bispo; Paulo S Pinheiro; Erin K Kobetz
Journal:  Cold Spring Harb Perspect Med       Date:  2020-06-01       Impact factor: 5.159

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.